Medasense Biometrics receives Innovative Technology contract from Vizient® for PMD-200™ with NOL technology
Contract awarded for products that bring potential improvement to healthcare industry.
BETHLEHEM, PA, UNITED STATES, August 4, 2026 /EINPresswire.com/ — Medasense Biometrics announced today that its PMD-200™ pain response (nociception) monitoring system with NOL technology has received an Innovative Technology contract from Vizient®, the largest provider-driven healthcare performance improvement company in the U.S.
The PMD-200 addresses a central challenge in anesthesia care: objectively monitoring a patient’s physiological response to pain during surgery, when the patient is under general anesthesia and unable to communicate.
The system’s NOL-Nociception Level Index® continuously monitors and quantifies nociception, the body’s physiological response to pain. This gives anesthesia clinicians objective information to help personalize analgesia for each patient and avoid both insufficient and excessive medication. The NOL Index uses AI-powered analysis of multiple physiological signals acquired through a proprietary sensor platform fitted on the patient’s finger. Clinical studies have shown that NOL-guided analgesia can empower healthcare providers to personalize analgesic dosing, improve patient outcomes and reduce postoperative pain.
